NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Updated: May 26, 2022
NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Dara-KPd
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.
Sponsor
Andrew Yee, MD
Collaborators
Amgen
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT04176718
Official Title: A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
First Posted : November 25, 2019
Click here for ClinicalTrials.gov
Drug: Daratumumab
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Dexamethasone
Location
United States, Massachusetts